Main Uses of Ebastina Sandoz

Ebastina Sandoz is an antihistamine medication used to manage symptoms associated with allergic reactions. It works by blocking the action of histamine, a natural substance in the body that triggers allergic symptoms when the immune system reacts to external allergens.

Allergic Rhinitis

This medication is primarily used to relieve symptoms of allergic rhinitis, which include:

• Sneezing: Reducing the frequency of sudden sneezing fits.
• Rhinorrhea: Managing a runny nose or excessive nasal discharge.
• Nasal Congestion: Helping to alleviate the feeling of a blocked nose.
• Itching: Reducing irritation in the nose and throat.

These symptoms may be seasonal, often referred to as hay fever (caused by pollen), or perennial, occurring year-round due to indoor allergens such as dust mites, pet dander, or mold.

Allergic Conjunctivitis

Ebastina Sandoz is also used to treat ocular symptoms associated with allergies. It helps manage:

• Redness of the eyes.
• Watery eyes (tearing).
• Itching or burning sensations in the eyes.

Urticaria (Hives)

In addition to respiratory and ocular symptoms, this medication is used to treat chronic idiopathic urticaria. This condition is characterized by the appearance of itchy red bumps or welts on the skin (hives). The treatment helps to:

• Reduce the number and size of hives.
• Alleviate the intensity of skin itching.

Benefits of Treatment

The primary benefit of Ebastina Sandoz is the improvement of quality of life by reducing the discomfort caused by allergic reactions. As a second-generation antihistamine, it is designed to provide relief with a lower likelihood of causing drowsiness compared to older antihistamine medications, allowing individuals to maintain their daily activities with fewer interruptions from allergy symptoms.

Regulatory References

1. Summary of Product Characteristics

Ebastina Sandoz is authorized for use based on specific population and health criteria documented in regulatory labeling. The medicine is established for adults and adolescents 12 years of age and above for allergic rhinitis. For chronic idiopathic urticaria (hives), use is specified only for adults aged 18 years and older. The safety and efficacy of this medicine are not established in children under 12 years of age.

The medicine is contraindicated and must not be used by individuals with a known hypersensitivity to the active substance (ebastine) or any of its excipients. Contraindication also extends to patients with specific hereditary metabolic disorders, such as total lactase deficiency or glucose-galactose malabsorption.

Use requires caution and special consideration in patients with certain pre-existing conditions. These include individuals with known QTc interval prolongation or hypokalaemia. While no dose adjustment is needed for mild to moderate kidney or liver impairment, the drug must be used with caution in cases of severe hepatic impairment. Furthermore, use is preferable to avoid during pregnancy and lactation due to limited clinical data in these states.

The official regulatory profile for Ebastine is defined by documented pharmacokinetic and pharmacodynamic interaction patterns with specific medicines and food. These documented interactions govern how the drug's systemic exposure is officially altered by co-administered substances.

Interacting Medicinal Products and Substances

Co-administration of Ebastine with certain substances may alter the drug's systemic exposure as defined in regulatory labeling:

Substance/Category	Official Interaction Statement
Azole Antifungals (e.g., Ketoconazole, Itraconazole)	Pharmacokinetic interaction resulting in increased plasma concentrations of Ebastine and its active metabolite, Carebastine.
Macrolide Antibiotics (e.g., Erythromycin)	Pharmacokinetic interaction resulting in increased plasma concentrations of Ebastine and Carebastine.
Rifampicin (Anti-tuberculosis agent)	Pharmacokinetic interaction leading to lower plasma concentrations and subsequent reduced antihistamine effects.
QTc-Prolonging Agents	Co-administration resulted in an approximate 10 msec QTc increase, which was not associated with clinically significant pharmacodynamic consequences.
Food	Co-administration causes a 1.5- to 2.0-fold increase in the plasma levels and AUC of the active metabolite, Carebastine.
Alcohol, Theophylline, Warfarin, Cimetidine, Diazepam	No interactions have been reported for these substances in official studies.

Population-Specific Interaction Note

Experience with doses over 10 mg is not available in patients with severe hepatic impairment, which is noted in regulatory documents as a population-specific consideration limiting the established interaction profile at higher doses.

Highly Selective Peripheral mathbfH1 -Receptor Blockade

The primary molecular action is mediated by the active metabolite, carboxylebastine, which acts as a competitive inverse agonist to stabilize peripheral Histamine mathbfH1 -Receptors in an inactive state. This targeted mechanism limits the Histamine-driven increase in vascular permeability and vasodilation, contributing to the limitation of Histamine-mediated vascular changes.

---

Mechanism of Non-Sedating Action and Sustained Effect

This action profile is governed by the drug's CNS selectivity. The metabolite's inability to significantly cross the blood-brain barrier confines its action to the peripheral systems, while its long biological half-life ensures continuous, high-level receptor occupation for a full 24-hour cycle. This results in the minimal occupation of central mathbfH1 -receptors alongside continuous blockade of peripheral Histamine effects.

---

Modulation of Inflammatory Cascades

Beyond direct receptor blockade, the mechanism engages in broader inflammatory cascade modulation by inhibiting intracellular signaling and the release of secondary pro-inflammatory mediators (like Leukotrienes) from immune cells. This complementary action promotes a reduction in subsequent mediator release, influencing the overall inflammatory cascade at the tissue level.

---

Functional Constraint of Antihistaminic Activity

The mechanism is dependent on the conversion of the parent drug to the active metabolite. Any physiological interference that accelerates the parent drug's breakdown can constrain the sustained formation of carboxylebastine, potentially diminishing the magnitude of peripheral mathbfH1 -receptor blockade.

How to Use Ebastina Sandoz

The usage instructions for Ebastine, the active substance in Ebastina Sandoz, define a precise protocol for administration across its available oral forms, which include film-coated tablets and orodispersible tablets (10 mg and 20 mg strengths). The approved route of administration is exclusively oral, and the regimen is standardized for once-daily intake.

Dosing Regimens and Special Population Rules

All standard dosing is set for adults and adolescents 12 years of age and older, as the use of these tablet strengths has not been established for younger children.

Usage Category	Official Administration Guidelines
Standard Adult/Adolescent Dose	10 mg ebastine once daily.
Maximum Dose	20 mg ebastine once daily for severe symptomatic conditions.
Severe Hepatic Insufficiency	Dose must not exceed 10 mg once daily.
Renal Impairment	No dose adjustment is required regardless of severity.

---

Administration Timing and Preparation

The medicine may be taken independently of meals, allowing flexibility as it can be administered with or without food.

Proper preparation is essential and depends on the specific form taken. Film-coated tablets must be swallowed whole (unchewed) with a glass of liquid. Conversely, the orodispersible tablets are designed to disperse quickly when placed on the tongue, and therefore do not require any liquid for consumption. Handling of the orodispersible tablet must be done carefully (by peeling the foil back) to avoid crushing the tablet.

Duration and Procedural Notes

The duration of use is determined by the specific condition and may be prolonged until symptomatic relief is achieved, based on clinical assessment. The overall use protocol requires that if a dose is forgotten, a double dose should not be taken to compensate for the missed administration.

Research Evidence / Overview of Studies for Ebastine Sandoz

Research Evidence for Allergic Rhinitis (Seasonal and Perennial)

Research exploring how symptoms change over time for allergic rhinitis is primarily based on short-term, randomized controlled trials (RCTs) that compare the medicine against both an inactive substance (placebo) and other selected allergy medications. These studies included populations of adults and adolescents with both seasonal and perennial forms of the condition.

The studies monitored outcomes related to physical discomfort, such as sneezing, nasal discharge, nasal itching, and ocular (eye) symptoms, using aggregated symptom scores. Findings describe patterns observed in the studies where measurements of perceived discomfort were tracked during the short-term treatment period compared to patients receiving placebo. Comparative studies reported measurements where symptom tracking differed among the medicines being evaluated.

---

Research Evidence for Chronic Idiopathic Urticaria (Hives)

The research base for Chronic Idiopathic Urticaria (CIU), a condition characterized by fluctuating or episodic manifestations of hives, is informed by data from double-blind, placebo-controlled randomized trials. These studies focused on patients whose symptoms persisted for at least six weeks, often excluding those with other specific forms of urticaria.

Studies monitored measurements related to inflammatory or irritative states, specifically examining scores for pruritus (itching) severity and the number and measured characteristics of wheals over defined time intervals. Findings describe patterns observed in the studies where measurements of pruritus and the measured characteristics of wheals were monitored in the observed populations during the short-term observation period compared to the placebo group.

---

Research Gaps and What Remains Uncertain

Follow-up durations were limited in many controlled studies, particularly when assessing the maintenance of symptom control over several months or years. What remains uncertain is that the long-term effects are not well characterized based on continuous, multi-year, placebo-controlled RCTs. Similarly, data for certain groups remain insufficient, including the pediatric population under the age of 12 and patients with severe hepatic (liver) impairment, where research involving this subgroup is based on limited studies. Comparative evidence is lacking for many direct, head-to-head comparisons against every other currently available second-generation antihistamine.

Key Studies & References

1. Package leaflet: Information for the patient Ebastine Sandoz 10 mg orodispersible tablets (Regulatory Information)

Common questions about Ebastina Sandoz (FAQ)

Q: Is Ebastina Sandoz the same as plain ebastine?

A: Ebastine is the name of the active substance that performs the anti-allergic action. Ebastina Sandoz is the specific brand-name medicinal product that contains this active ingredient, as defined in the official labeling.

---

Q: What does 'Sandoz' mean in the name of the medicine?

A: The name Sandoz refers to the pharmaceutical company that manufactures and supplies this particular medicinal product containing the active ingredient ebastine. This is a common practice in drug naming to identify the specific product originator.

---

Q: What kind of allergy symptoms is Ebastina Sandoz used for?

A: This medicine is indicated for the relief of symptoms related to allergies, based on official regulatory documents. These uses include seasonal and perennial allergic rhinitis, where it is used for the symptomatic relief of conditions, including symptoms like sneezing, runny nose, and itchy eyes. It is also indicated for treating chronic idiopathic urticaria, commonly known as hives.

---

Q: Does Ebastina Sandoz help with nasal congestion?

A: According to regulatory documents defining its authorized use, the medicine is indicated for the symptomatic relief of allergic rhinitis. This indication includes relief for symptoms such as a runny nose or a stuffy nose, which is a way of describing nasal congestion.

---

Q: How long does it typically take for Ebastina Sandoz to start working?

A: Studies on the medicine's activity indicate that the active form of the drug typically reaches its highest level in the bloodstream in about 2.6 to 4 hours after the tablet is taken. This measurement of maximum concentration suggests the time frame in which the medication is expected to exert its effect.

---

Q: Why is Ebastina Sandoz classified as a non-sedating antihistamine?

A: This medicine is classified as non-sedating because of its design and mechanism. Studies show that the drug's active form has a minimal ability to cross the blood-brain barrier. This means its main action is confined to the peripheral parts of the body, limiting the effect on the central nervous system that causes drowsiness.

---

Q: Are there different strengths of Ebastina Sandoz available?

A: The medicine is available in two different strengths, based on official product information. These include 10 mg and 20 mg doses. These strengths are available in the form of film-coated tablets and orodispersible tablets.

---

Q: Is Ebastina Sandoz available in a liquid or suspension form?

A: The active ingredient, ebastine, is offered in multiple physical forms, depending on the product and region. These typically include film-coated tablets and orodispersible tablets (which dissolve quickly on the tongue). In some regions, a liquid or oral suspension form may also be available.

---

Q: Can Ebastina Sandoz be crushed or split?

A: The method of administration depends on the form of the medicine. The standard film-coated tablets must be swallowed whole and unchewed. The orodispersible tablets are designed to dissolve quickly on the tongue and must be handled carefully to avoid crushing them before placement.

---

Q: Is it okay to take Ebastina Sandoz every day during allergy season?

A: The duration of use is generally guided by the specific condition. Official product documents state that use may be prolonged until symptomatic relief is achieved. Clinical experience for allergic rhinitis extends up to one year of continuous use.

---

Q: Is it possible to have an allergic reaction to Ebastina Sandoz itself?

A: Official product safety information states that the medicine is contraindicated if a person has a known hypersensitivity (allergy) to the active substance, ebastine, or to any of its inactive components (excipients). Rare, serious adverse reactions like anaphylaxis, which is a type of severe allergic reaction, are also documented.

---

Q: Can I take Ebastina Sandoz if I am currently using antibiotics?

A: Official interaction studies indicate potential for altered drug levels when Ebastina Sandoz is co-administered with certain medicines. Co-administration with macrolide antibiotics (like erythromycin) is associated with increased concentrations of the drug in the body. Co-administration with rifampicin is associated with lower drug concentrations and a reduced antihistamine effect.

---

Q: Is Ebastina Sandoz suitable for people with kidney impairment?

A: Regulatory documents state that no dose adjustment is necessary for patients with mild, moderate, or severe renal (kidney) impairment. Caution is generally advised for use in cases of severe hepatic (liver) impairment.

---

Q: Is it normal to feel dry mouth after taking Ebastina Sandoz?

A: Dry mouth is listed in official product information as a common adverse reaction. This means that, based on clinical data, it is a frequently reported side effect that may affect up to 1 in 10 people studied.

---

Q: Is it normal to feel nauseous when starting Ebastina Sandoz?

A: Nausea is included in the official adverse reaction data for this medicine, but it is classified as a rare effect. This means that based on clinical data, it may affect up to 1 in 1,000 people studied.

---

Q: What is the recommended storage temperature for Ebastina Sandoz tablets?

A: Official regulatory information states that the medicine does not require special storage conditions regarding temperature. It should be kept at room temperature, typically between 1°C and 30°C. It must also be stored in its original package to provide protection from light.

---

Q: Do studies show Ebastina Sandoz is effective for indoor dust allergies?

A: Official indications for the medicine include perennial allergic rhinitis. This is the regulatory term for year-round allergy symptoms, which are often caused by common indoor allergens like dust mites. Therefore, its authorized use covers the condition caused by such triggers.

---

Q: Is the long-term safety profile of Ebastina Sandoz established?

A: Research overviews in official documents indicate that the long-term safety profile is not well characterized based on continuous, multi-year, placebo-controlled trials. This is because follow-up durations in many controlled studies were limited.

Storage and Disposal Requirements for Ebastina Sandoz

Storage Conditions

Official regulatory information indicates that this medicine does not require any special storage conditions in terms of temperature. However, Ebastina Sandoz must be stored in the original package to ensure protection from light. It is mandatory that the medicine be kept out of the sight and reach of children.

Container and Stability

The product should not be used after the expiry date stated on the carton and blister. The orodispersible tablet must be taken out of the blister carefully with dry hands for immediate use.

Waste Handling

This medicine must not be thrown away via wastewater or household waste. Disposal should be managed by asking a pharmacist how to dispose of medicines no longer needed. This measure helps protect the environment.